Dr. Ashwin Pachaatt Vinod (@pachaatt) header
Dr. Ashwin Pachaatt Vinod (@pachaatt) profile picture

Liver specialist. Alumnus Dept. of Hepatology-PGIMER Chandigarh/ Dept. of Medicine AIIMS New Delhi/ AIIMS Raipur.

Joined July 2021
Photo by Dr. Ashwin Pachaatt Vinod (@pachaatt)Photo by Dr. Ashwin Pachaatt Vinod (@pachaatt)Photo by Dr. Ashwin Pachaatt Vinod (@pachaatt)Photo by Dr. Ashwin Pachaatt Vinod (@pachaatt)Photo by Dr. Ashwin Pachaatt Vinod (@pachaatt)Photo by Dr. Ashwin Pachaatt Vinod (@pachaatt)Photo by Dr. Ashwin Pachaatt Vinod (@pachaatt)Photo by Dr. Ashwin Pachaatt Vinod (@pachaatt)Photo by Dr. Ashwin Pachaatt Vinod (@pachaatt)Photo by Dr. Ashwin Pachaatt Vinod (@pachaatt)
A dream that began years ago has finally come true — Dr. Ashwin P Vinod, MBBS, MD (Medicine), DM (Hepatology) it is! Endless gratitude to Dept. of Hepatology, PGIMER & its incredible faculty for shaping my journey. Thank you all for being part of this dream. @HepatologyPGI
6 mon back, I made this doodle, took a print-out and stuck it on the ceiling just above my bed. Today I am one step closer to that dream. Rank 1, Hepatology INI SS. Cheers to 3 years of residency @ PGI Chandigarh, the Mecca of Hepatology in India. @HepatologyPGI #Hepatology
5
2
83
6,497
Dr. Ashwin Pachaatt Vinod retweeted
Read via bit.ly/4zs86Fe "Review Article: Cirrhosis Recompensation- Definition, Natural History, Clinical Implications and Considerations for Clinical Trials" #livertwitter #cirrhosis #clinicaltrials
32
45
2,504
Dr. Ashwin Pachaatt Vinod retweeted
This week in medicine 1. FDA approves the first factor XIa inhibitor(!), Bayer's asundexian, for secondary stroke prevention. 2. Australian researchers find that resistance training, alongside tirzepatide, reduces lean mass loss and improves muscle strength versus tirzepatide alone (with no difference in weight loss). 3. Regeneron's liver-targeted CIDEB siRNA, discovered by mining human genetics, reduced liver fat in a first-in-human trial, ~matching retatrutide's unprecedented efficacy. 4. CRISPR Therapeutics' one-time ANGPTL3 gene editor reduced triglycerides and cholesterol, in severe hypertriglyceridaemia, in an early human trial. 5. Beam's one-time base-edited stem cell therapy met its pivotal endpoint in sickle cell disease: FDA submission planned this year. 6. Intellia's in vivo CRISPR therapy for hereditary angioedema maintained suppression of plasma kallikrein for up to four years after a single infusion (with fewer attacks than with patients' previous prophylaxis). 7. Allogene's off-the-shelf CD19×CD70 CAR-T therapy produced responses in patients with systemic sclerosis, including without lymphodepleting chemotherapy, in an early phase 1 trial. 8. Vir's combination of an siRNA (elebsiran) and antibody (tobevibart) eradicated hepatitis D RNA in ~80% of patients, in a phase 3 trial. 9. Beeline's oral TLR7/8 inhibitor achieved clinical responses in systemic lupus erythematosus in a phase 2 trial (a new approach in lupus). 10. Lilly's oral GLP1, orforglipron, improved obstructive sleep apnoea in two phase 3 trials.
6
45
2
345
32,475
Dr. Ashwin Pachaatt Vinod retweeted
Original Article: Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (phase 3 TRIUMPH-1 trial) nej.md/4ycgSHz Editorial: A Triple Incretin Agonist for Obesity, Osteoarthritis, and Sleep Apnea nej.md/4izSuJs #Endocrinology #Rheumatology
22
105
12
305
40,800
Dr. Ashwin Pachaatt Vinod retweeted
📢Anyone caring for patients with alcohol-associated liver disease! This one-pager summarizes the @AASLDtweets guideline on ALD. It is a must-have for all residents, hospitalists, and GI Fellows! @LiverFellow @geneyim #MedEd
🧭 Guidelines Corner 🍷 Alcohol-Associated Liver Disease affects millions each year, but what do the newest #AASLD guidelines actually recommend? @ElinaStoffel breaks it down in a crisp, high-yield summary ✨ 🔖Read it here ➡️ aasld.org/liver-fellow-netwo… DOI: 10.1002/hep.30866
5
49
1
130
22,580
Dr. Ashwin Pachaatt Vinod retweeted
🔥 Hot topic in #HCC! New review in @NatRevClinOncol explores LRT + immunotherapy in unresectable HCC 📊 5 phase III trials, 5 positive PFS results. How should we act on this consistent evidence? These trials were designed and powered for PFS, NOT OS. 🔗 rdcu.be/W9AbX4tcp2va
1
29
47
2,772
Dr. Ashwin Pachaatt Vinod retweeted
Everything you need to know about liver biopsy! The first @AASLDtweets EXPO is on biopsy and it is online now without paywall: ovid.com/jnls/hep/fulltext/1…
1
70
1
215
13,908
Dr. Ashwin Pachaatt Vinod retweeted
Mildly schizophrenic idea: BBB-penetrant adenosine receptor degrader to resensitize you to caffeine
Exhaustive list of degraders that cross the blood-brain barrier in humans: 1. Arvinas' LRRK2 degrader, in trials for Parkinson's. 2. Nurix's BTK degrader, in trials for CNS lymphoma. 3. Monte Rosa's NEK7 degrader, in trials for inflammation. Almost total white space.
7
7
1
112
12,240
Dr. Ashwin Pachaatt Vinod retweeted
#Baveno VIII consensus in portal hypertension #CSPH Full Consensus Report now @JHepatology @EASLnews journal-of-hepatology.eu/art…
1
82
3
199
10,062
Dr. Ashwin Pachaatt Vinod retweeted
Hepaticoliths can be challenging to manage and may involve a spectrum of endoscopic or cholangioscopic measures before finally resolving for surgical interventions.
1
5
11
413
Dr. Ashwin Pachaatt Vinod retweeted
Now is the best time in the history of cirrhosis care. And it will only get better. This week we release the first set of guidelines on preventive care in cirrhosis in @AmJGastro @AmCollegeGastro Open access: ovid.com/jnls/ajg/fulltext/1…
1
31
3
101
12,740
Dr. Ashwin Pachaatt Vinod retweeted
🟣Corticosteroids in severe alcohol-related hepatitis: A multicenter randomized clinical trial 🔓#OpenAccess at👉jhep-reports.eu/article/S258… #AH #LiverTwitter #LiverHealth #LiverX
3
21
68
7,773
Dr. Ashwin Pachaatt Vinod retweeted
#BavenoVIII – @BavenoCoop out in @JHepatology Advancing consensus in portal hypertension journal-of-hepatology.eu/art…
37
98
5,703
Dr. Ashwin Pachaatt Vinod retweeted
#EvidenceCorner Could we finally cure Hepatitis B? 🏅 Bepirovirsen = ✅ functional cure in ~1 in 5 patients vs 🚫 none with placebo — a potential game-changer for chronic HBV!  See 🔍 Urmi Chaudhuri's review of the B-Well Phase 3 Trials 📝 @NEJM! #LiverTwitter #GITwitter #MedEd
3
19
66
4,044
Dr. Ashwin Pachaatt Vinod retweeted
Summary of the 2026 Baveno VIII guidelines relevant to variceal bleeding💡🩸
🤖 Made with AI
3
96
2
270
17,687
Dr. Ashwin Pachaatt Vinod retweeted
LiverSteps Kids has expanded 🍁 Now live: • MASLD • Pediatric cholestasis • Autoimmune hepatitis • Understanding Liver Tests & Procedures And now 🎮 interactive games so children can learn through play—not just read about liver disease. liverstepskids.ca
1
1
1
102
Dr. Ashwin Pachaatt Vinod retweeted
📚 New LFN Guidelines infographic! A practical guide to noninvasive liver disease assessment (NILDA) for fibrosis, steatosis, and portal hypertension. Save it for your next rotation 👇 ✍️ @BlaneyMD @muaazmasood @SarahUttal @DrSoeThihaMaung aasld.org/liver-fellow-netwo…
1
38
113
7,324
Dr. Ashwin Pachaatt Vinod retweeted
Breaking: FDA approves tirzepatide to reduce cardiovascular risk in adults with type 2 diabetes at high CV risk, based on results from SURPASS-CVOT. A major milestone for tirzepatide, adding cardiovascular risk reduction to its growing clinical profile. lilly.mediaroom.com/2026-08-…
9
64
1
208
8,342
Dr. Ashwin Pachaatt Vinod retweeted
If you have fatty liver (MASLD/MAFLD), you’ve probably been told that Just do BRISK WALKING But most people don’t know what “brisk” actually means physiologically. A short thread 🧵
12
89
4
476
162,771
Dr. Ashwin Pachaatt Vinod retweeted
GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read the full review: nej.md/4sUFlys
8
358
9
1,153
74,098